Novo Nordisk is under pressure from Eli Lilly in the rapidly growing GLP-1 market, impacting its growth prospects and stock valuation. Despite having a strong pipeline including new oral and higher-dose Wegovy products, Novo Nordisk's current injectable offerings lag behind Eli Lilly's. Upcoming patent expirations also raise concerns about long-term sustainability. The stock is valued at $29 per share, below current prices, leading to a 'Hold' rating due to competitive challenges and limited market share gains.
The European Commission has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 receptor agonist for weight management across the EU. This approval covers adults with obesity or overweight with related health issues and follows positive clinica...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
